千红制药(002550) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥511,943,232.28, representing a 3.35% increase year-over-year, while the year-to-date revenue reached ¥1,648,829,042.01, up 20.50% compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥66,541,577.71, a decrease of 33.97% year-over-year, with a year-to-date net profit of ¥268,398,353.54, which is an increase of 41.32% compared to the previous year[6]. - Basic earnings per share for Q3 2022 were ¥0.0528, down 34.49% year-over-year, while the year-to-date basic earnings per share were ¥0.2142, an increase of 40.74%[6]. - Total operating revenue for the third quarter reached ¥1,648,829,042.01, an increase of 20.5% compared to ¥1,368,373,802.06 in the same period last year[27]. - Net profit for the quarter was ¥257,198,189.23, representing a 40.0% increase from ¥183,985,974.26 in the previous year[29]. - The total comprehensive income attributable to the parent company was ¥264,805,231.67, an increase from ¥189,898,330.57 in the previous period[32]. - Basic and diluted earnings per share were both ¥0.2142, compared to ¥0.1522 in the previous period[32]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥2,770,648,124.67, a 10.45% increase from the end of the previous year[6]. - The company's total assets increased to ¥2,770,648,124.67, compared to ¥2,508,397,996.17 at the end of the previous period, reflecting a growth of 10.4%[26]. - Total liabilities rose to ¥403,958,664.15, up from ¥390,237,603.01, indicating a 1.8% increase[26]. - Shareholders' equity attributable to the parent company reached ¥2,386,979,711.00, which is a 12.21% increase compared to the end of the previous year[6]. - The company's equity attributable to shareholders reached ¥2,386,979,711.00, a significant increase from ¥2,127,250,479.33, marking a growth of 12.2%[26]. Cash Flow - The net cash flow from operating activities for the year-to-date period was -¥54,760,163.91, reflecting a significant decrease of 875.30% compared to the same period last year[6]. - Cash inflow from operating activities totaled ¥1,680,056,558.66, up from ¥1,486,651,144.16 in the previous period[33]. - The net cash flow from operating activities was -¥54,760,163.91, a decline from a positive cash flow of ¥7,063,071.14 in the previous period[36]. - Cash outflow from investing activities was ¥490,689,449.55, compared to ¥321,211,073.04 in the previous period[36]. - The net cash flow from financing activities was ¥56,975,102.90, a recovery from -¥149,699,278.54 in the previous period[36]. - The company received cash from financing activities totaling ¥600,480,000.00, significantly higher than ¥37,006,125.44 in the previous period[36]. - The cash and cash equivalents at the end of the period were ¥508,855,227.02, down from ¥528,478,815.55 in the previous period[36]. Operational Costs and Expenses - The company reported a 32.94% increase in operating costs year-over-year, primarily due to increased sales during the reporting period[11]. - Total operating costs amounted to ¥1,392,256,770.35, up 15.6% from ¥1,205,103,296.49 year-over-year[27]. - Research and development expenses for the quarter were ¥47,814,735.93, compared to ¥44,031,958.91 in the same period last year, reflecting a 6.3% increase[29]. - Financial expenses showed a significant increase, totaling -¥88,141,450.78, compared to -¥10,969,242.25 in the previous year[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 70,125[15]. - The company has a significant shareholder, Wang Yaofang, holding 19.96% of the shares, totaling 255,402,000 shares[15]. - The top ten shareholders include several individuals and investment funds, with the largest holding being Wang Yaofang[15]. Strategic Initiatives - The company plans to invest approximately 600 million CNY in a new raw material drug production base project in Zhongxiang City, which will be constructed in two phases[19]. - The company is focusing on expanding its product lines, including polysaccharide products and high-end anti-thrombotic drugs in the new production base[19]. - The company is actively pursuing strategic initiatives to enhance its market presence and product offerings[19]. Other Financial Metrics - The company received government compensation of ¥57,556,734.94, contributing to an increase in other income[7]. - The company's short-term borrowings increased by 68.30% compared to the beginning of the period, attributed to the need for operational funds[11]. - The company’s cash flow from investing activities decreased by ¥30,580,620.00 year-over-year, mainly due to increased investments in financial products[11]. - Current assets include cash of 508,855,227.02 CNY and accounts receivable of 470,218,117.45 CNY, showing an increase from the previous period[20]. - Inventory at the end of the reporting period was 494,418,074.88 CNY, up from 400,630,285.02 CNY in the previous period[20]. - The company paid ¥165,298,224.09 in cash to employees, a decrease from ¥189,706,232.14 in the previous period[33]. - The company reported a foreign exchange impact on cash and cash equivalents of ¥50,705,760.95, compared to ¥11,431,322.98 in the previous period[36].